Discussion Papers
The Institute´s Discussion Paper Series
M. Schlander in cooperation with R. Schaefer (2024):
The InnoValHC Discussion Paper Series (2005-2023): Discussion / Technical / Working Paper [Shortlist].
InnoValHC Discussion Paper Series
(2005-2023)
The Heidelberg Health Economic Summer Schools 2006 – 2023: History, International Evaluation & Outlook
R. Schaefer, M. Schlander (2023):
The Heidelberg Health Economics Summer [& Winter] Schools 2006-2023: History, International Evaluation (2023) & Outlook.
InnoValHC Discussion Paper No. 36 / 2023
(ISBN 978 3 941609 34 1)
Swiss Social Preferences – Briefing Document: Essential Insights from the SoPHI Study
M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, D. Hernandez, R. Schaefer – on behalf of the ESPM Project Group (2021):
The Swiss Social Preferences for Health Care Interventions (“SoPHI”) Study – Briefing on Essential Study Insights & Policy Implications.
InnoValHC Discussion Paper No. 35 / 2021
(ISBN 978 3 941609 33 4)
Economic Valuation of Life: The Value of a Statistical Life Year (VSLY) in Europe
M. Schlander, R. Schaefer, O. Schwarz (2017):
The Economic Value of a Statistical Life Year in Europe: Report of a Systematic Review [German].
InnoValHC Discussion Paper No. 34 / 2017
(ISBN 978 3 941609 32 7)
Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review 2016: An International Perspective
M. Schlander (2016):
Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review 2016: An International Perspective [Expert Statement].
InnoValHC Discussion Paper No. 33 / 2016
Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare Diseases (URDs) in Europe
M. Schlander, K. Stenner, A. Gandjour (2015):
Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare Diseases (URDs) in Europe.
InnoValHC Discussion Paper No. 32 / 2015
(ISBN 978 3 941609 31 0)
Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs)
M. Schlander, S. Holm, E. Nord, J. Richardson, S. Garattini, P. Kolominsky-Rabas, D. Marshall, U. Persson, M. Postma, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi (2015):
Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs).
InnoValHC Discussion Paper No. 31 / 2015
(ISBN 978 3 941609 30 3)
Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe
M. Schlander, C. Adarkwah, A. Gandjour (2014):
Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe.
InnoValHC Discussion Paper No. 30 / 2014
(ISBN 978 3 941609 29 7)
Beyond Incremental Cost per QALY Ratios: The Need for Alternative Methods to Evaluate Medical Interventions for URDs
M. Schlander, S. Garattini, S. Holm with P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà-Morales, K. Tolley, M. Toumi (2013):
Beyond Incremental Cost per QALY Ratios: The Need for Alternative Methods to Evaluate Medical Interventions for Ultra-Rare Disorders (URDs).
InnoValHC Discussion Paper No. 29 / 2013
(ISBN 978 3 941609 28 0)
Determining the Price for Pharmaceuticals in Germany
A. Gandjour, A. Gafni, M. Schlander (2013):
Determining the Price for Pharmaceuticals in Germany: Comparing a Shortcut for IQWiG’s Efficiency Frontier Method with the Price Set by the Manufacturer for Ticagrelor.
InnoValHC Discussion Paper No. 28 / 2013
(ISBN 978 3 941609 27 3)
Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders (URDs)
M. Schlander, S. Garattini, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà-Morales, K. Tolley, M. Toumi (2013):
Consensus Statement: Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders (URDs).
InnoValHC Discussion Paper No. 27 / 2013
(ISBN 978 3 941609 26 6)
Swiss HTA Consensus / Umsetzungspapier 6: Wirtschaftlichkeitsbewertung
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 6/2012: Wirtschaftlichkeitsbewertung.
InnoValHC Discussion Paper No. 26 / 2012
(ISBN 978 3 941609 25 9)
Swiss HTA Consensus / Umsetzungspapier 5: Nutzenbewertung
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 5/2012: Nutzenbewertung.
InnoValHC Discussion Paper No. 25 / 2012
(ISBN 978 3 941609 24 2)
Swiss HTA Consensus / Umsetzungspapier 4: Konkretisierung der WZW-Kriterien
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 4/2012: Konkretisierung der WZW-Kriterien.
InnoValHC Discussion Paper No. 24 / 2012
(ISBN 978 3 941609 23 5)
Swiss HTA Consensus / Umsetzungspapier 3: Complete (c-) HTAs
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 3/2012: Complete (c-) HTAs.
InnoValHC Discussion Paper No. 23 / 2012
(ISBN 978 3 941609 22 8)
Swiss HTA Consensus / Umsetzungspapier 2: Rapid (r-) HTAs
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 2/2012: Rapid (r-) HTAs.
InnoValHC Discussion Paper No. 22 / 2012
(ISBN 978 3 941609 21 1)
Swiss HTA Consensus / Umsetzungspapier 1: Institutionelles
M. Schlander, H. Sandmeier, C. Affolter with C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft and P. Suter (2012):
Swiss HTA Consensus / Schweizer HTA-Konsensus. Umsetzungspapier 1/2012: Institutionelles.
InnoValHC Discussion Paper No. 21 / 2012
(ISBN 978 3 941609 20 4)
SwissHTA Multi-Stakeholder Consensus: Projekt-Leitsätze
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2012): SwissHTA Multi-Stakeholder Consensus Project / Schweizer HTA-Konsensus-Projekt: Leitsätze.
InnoValHC Discussion Paper No. 20 / 2012
(ISBN 978 3 941609 19 8)
SwissHTA Multi-Stakeholder Consensus: Guiding Principles
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2012): SwissHTA Multi-Stakeholder Consensus: Guiding Principles.
InnoValHC Discussion Paper No. 19 / 2012
(ISBN 978 3 941609 18 1)
SwissHTA Multi-Stakeholder Consensus: Cornerstones for Further Development in Switzerland
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2011): SwissHTA Multi-Stakeholder Consensus: Cornerstones for Further Development in Switzerland.
InnoValHC Discussion Paper No. 18 / 2011
(ISBN 978 3 941609 17 4)
SwissHTA Multi-Stakeholder Consensus: Eckpunkte für die Weiterentwicklung in der Schweiz
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2011): SwissHTA Multi-Stakeholder Consensus: Eckpunkte für die Weiterentwicklung in der Schweiz.
InnoValHC Discussion Paper No. 17 / 2011
(ISBN 978 3 941609 16 7)
SwissHTA Multi-Stakeholder Consensus / Eckpunkte für die Weiterentwicklung in der Schweiz: Anhang / Glossar / Dokumentation
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2011): SwissHTA Multi-Stakeholder Consensus / Eckpunkte für die Weiterentwicklung in der Schweiz: Anhang / Glossar / Dokumentation.
InnoValHC Discussion Paper No. 16 / 2011
(ISBN 978 3 941609 15 0)
Swiss HTA Consensus: Value and Valuation of Health Technologies
M. Schlander, H. Sandmeier, C. Affolter, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter (2011):
Swiss HTA Consensus / Schweizer HTA-Konsensus: «Value and Valuation of Health Technologies». Full Documentation of Primary Project Output.
InnoValHC Discussion Paper No. 15 / 2011
(ISBN 978 3 941609 14 3)
Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden / Germany
M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer (2005):
Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden / Germany: Administrative Prevalence & Implications for Health Care Provision and Future Research.
InnoValHC Discussion Paper No. 00 / 2005